Table 2 Association between risk stratification and response to treatment with the studied parameters
| Â | Risk stratification | P value | Response to treatment | P value | |||
|---|---|---|---|---|---|---|---|
Standard risk | Intermediate risk | High risk | Non-responders | Responders | |||
No. = 41 | No. = 10 | No. = 9 | No. = 21 | No. = 39 | |||
Sex | |||||||
 Females | 16 (39.0%) | 4 (40.0%) | 3 (33.3%) | 0.944 | 10 (47.6%) | 13 (33.3%) | 0.278 |
 Males | 25 (61.0%) | 6 (60.0%) | 6 (66.7%) |  | 11 (52.4%) | 26 (66.7%) |  |
HB (gm/dL) | |||||||
 ≥ 10 | 20 (48.8%) | 0 (0.0%) | 0 (0.0%) | 0.001 | 1 (4.8%) | 19 (48.7%) | 0.001 |
 < 10 | 21 (51.2%) | 10 (100.0%) | 9 (100.0%) |  | 20 (95.2%) | 20 (51.3%) |  |
Creat (mg/dL) | |||||||
 ≤ 2 | 29 (70.7%) | 4 (40.0%) | 4 (44.4%) | 0.103 | 11 (52.4%) | 26 (66.7%) | 0.278 |
 > 2 | 12 (29.3%) | 6 (60.0%) | 5 (55.6%) |  | 10 (47.6%) | 13 (33.3%) |  |
Ca (mg/dL) | |||||||
 ≤ 11 | 32 (78.0%) | 4 (40.0%) | 1 (11.1%) | 0.000 | 9 (42.9%) | 28 (71.8%) | 0.028 |
 > 11 | 9 (22.0%) | 6 (60.0%) | 8 (88.9%) |  | 12 (57.1%) | 11 (28.2%) |  |
 Positive | 41 (100.0%) | 10 (100.0%) | 9 (100.0%) |  |  |  |  |
IPT | |||||||
 Lambda | 9 (22.0%) | 7 (70.0%) | 8 (88.9%) | 0.000 | 16 (76.2%) | 8 (20.5%) | 0.000 |
 Kappa | 32 (78.0%) | 3 (30.0%) | 1 (11.1%) |  | 5 (23.8%) | 31 (79.5%) |  |
ISS | |||||||
 I | 21 (51.2%) | 2 (20.0%) | 2 (22.2%) | 0.000 | 3 (14.3%) | 22 (56.4%) | 0.000 |
 II | 15 (36.6%) | 2 (20.0%) | 0 (0.0%) |  | 2 (9.5%) | 15 (38.5%) |  |
 III | 5 (12.2%) | 6 (60.0%) | 7 (77.8%) |  | 16 (76.2%) | 2 (5.1%) |  |
RISS | |||||||
 I | 7 (17.1%) | 0 (0.0%) | 0 (0.0%) | 0.000 | 3 (14.3%) | 4 (10.3%) | 0.003 |
 II | 34 (82.9%) | 3 (30.0%) | 2 (22.2%) |  | 8 (38.1%) | 31 (79.5%) |  |
 III | 0 (0.0%) | 7 (70.0%) | 7 (77.8%) |  | 10 (47.6%) | 4 (10.3%) |  |